The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer
- 1 July 1995
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 6 (6) , 581-587
- https://doi.org/10.1093/oxfordjournals.annonc.a059248
Abstract
Evaluation of the prognostic significance of a group of tumour markers and their ability to predict response to chemotherapy may allow better targeting of palliative treatment in advanced colorectal cancer. Using a prospectively acquired database of 377 patients (pts) with advanced colorectal adenocarcinoma, the prognostic significance of serum CEA (342 pts), 0HCG (203 pts), AFP (208 pts), CA125 (150 pts), CA19-9 (76 pts) as well as C-erb B-2 (197 pts), pHCG (197 pts) immunohistochemistry was investigated. Serum markers were taken prior to 5-FU based chemotherapy and immunohistochemistry was performed on diagnostic samples. Tumour markers of poor prognostic significance in the univariate analysis were CEA > 5 [ig/1 (p ─ 0.006; median survival (MS) 59 weeks vs. 38 weeks) and CA125 > 35 U/ml (p ─ 0.01; MS 51 weeks vs. 30 weeks). Tumour markers elevated at greater than 10 times the normal value which correlated with a poor prognosis were CEA (p─0.001; MS 47 weeks vs. 35 weeks), Serum 0HCG (p< 0.0001; MS 44 weeks vs. 7 weeks) and CA125 (p < 0.0001; MS 38 weeks vs. 15 weeks). Poor performance status (>2) and poorly differentiated tumour histology were also correlated to poor survival. In the multivariate analysis, tumour markers of independent poor prognosis were CEA > 5 [ig/1 (Hazard Ratio (HR) 1.8; 95% Confidence Internal (CI) 2.8−1.2), CEA > 50 ng/1 (HR 1.6; CI 2.1−1.2), CA125 > 35 U/ml (HR 1.5; CI 2.3−1.0), CA125 > 350 U/ml (HR 5.0; CI 9.6−2.6) and serum PHCG > 40 IU/1 (HR 11.7; CI 30−4.5). Poor performance status (HR 6.7−5.0) and poorly differentiated histology (HR 2.8-1.0) were the other important factors in the model. No pretreatment tumour marker correlated with response to chemotherapy. This is the largest prognostic study of each tumour marker in advanced disease and it clarifies previous conflicting reports. Serum AFT, CA19-9 and immunohisto-chemical stains PHCG and C-erb B-2 have no prognostic significance. Serum CEA, PHCG, CA125 in advanced colorectal cancer prior to chemotherapy do convey an independent poor prognosis which may reflect not just tumour burden but aggressive biology.Keywords
This publication has 37 references indexed in Scilit:
- c-erbB-2/neu in colorectal carcinoma: A potential prognostic value?European Journal Of Cancer, 1993
- HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.Journal of Clinical Pathology, 1992
- Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion moleculePublished by Elsevier ,1989
- Determinants of survival in patients with unresectable colorectal liver metastasesJournal of Surgical Oncology, 1989
- Human chorionic gonadotropin in colorectal carcinoma an immunohistochemical studyCancer, 1987
- Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.Gut, 1987
- Human chorionic gonadotrophin expression in colorectal adenocarcinomaDiseases of the Colon & Rectum, 1986
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- An immunohistochemical study of the significance of HCG secretion by large bowel adenocarcinomata.Journal of Clinical Pathology, 1979
- Human chorionic gonadotrophins (hCG) in nontrophoblastic neoplasms.Assessment of abnormalities of hCG and CEA in bronchogenic and digestive neoplasmsCancer, 1976